Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …

Chimeric antigen receptor T-cell (CAR-T) therapy is a novel anticancer therapy using
autologous or allogeneic T-cells. To date, six CAR-T therapies for specific B-cell acute …

Cancer is a disease that undergoes selective pressure to evolve during its progression,
becoming increasingly heterogeneous. Tumoral heterogeneity can dictate therapeutic …

Given advancements in large-scale data and AI, integrating multimodal artificial intelligence
into cancer research can enhance our understanding of tumor behavior by simultaneously …

Regulatory T cells (Tregs) are responsible for maintaining immune homeostasis by
controlling immune responses. They can be characterized by concomitant expression of …

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma
which that highly aggressive and heterogeneous. Glycolysis has been implicated in the …

Immune cell effector therapies, including chimeric antigen receptor (CAR)-T cells, T-cell
receptor (TCR) T cells, natural killer (NK) cells, and macrophage-based therapies, represent …

Simple Summary The present study describes a primary mediastinal large B-cell lymphoma
(PMBL) cohort on the morphological, immunohistochemical, and molecular levels, allowing …

Lymphoma is known as the third most common malignancy in children, and its prevalence
and mortality are increasing. Common treatments, including chemotherapy, radiotherapy …

Humans are in a complex symbiotic relationship with a wide range of microbial organisms,
including bacteria, viruses, and fungi. The evolution and composition of the human …